Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.40 |
| ▸ | JAK1 | P23458 | 7/20 | 0.39 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | BRAF | P15056 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440002 | 0.94 | JAK1 (0.39) | AAK1JAK1JAK3AKT1JAK2 | |
| SCHEMBL4437532 | 0.79 | JAK3 (0.37) | JAK1JAK3JAK2BRAF | |
| SCHEMBL4437639 | 0.78 | JAK3 (0.37) | JAK1JAK3JAK2 | |
| SCHEMBL3652666 | 0.77 | AKT1 (0.38) | JAK1JAK3AKT1JAK2 | |
| SCHEMBL3655831 | 0.75 | JAK1 (0.38) | JAK1JAK3AKT1JAK2BRAF | |
| SCHEMBL3655001 | 0.74 | JAK1 (0.38) | JAK1JAK3AKT1JAK2BRAF | |
| SCHEMBL3647805 | 0.74 | JAK3 (0.38) | JAK1JAK3JAK2 | |
| SCHEMBL3657737 | 0.73 | JAK3 (0.40) | JAK1JAK3AKT1JAK2 | |
| SCHEMBL3653928 | 0.72 | JAK3 (0.39) | JAK1JAK3AKT1JAK2 | |
| SCHEMBL3488971 | 0.72 | AKT1 (0.48) | AAK1JAK3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125805-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |